Inavolisib

And since then, the problem has been the toxicity issues with these drugs.

Inavolisib causes some hyperglycemia.

The patients who've been eligible have essentially normal glucose, uh, and hemoglobin A1C, but we have trials ongoing now looking at, uh, pro- proactive management of hyperglycemia in patients with Type 2 diabetes and with pre-diabetes.

So they're testing inavolisib in, uh, ENAVO-one-twenty-two, I think, uh, that is evaluating patients like a maintenance approach.

Uh, and the arm that recently closed to accrual, that should be presented in the near future, uh, is a dose expansion looking at elacestrant and capivasertib.

So that will be really helpful because, to my knowledge, there's-- that's gonna be one of the largest groups that's, that we have data on, where you have an oral SERD and a drug that targets the PI3 kinase pathway.

All right, let's talk a little bit about Inavolisib.

We were talking about the Inava120 study.

And since then, the problem has been the toxicity issues with these drugs.

Inavolisib causes some hyperglycemia.

The patients who've been eligible have essentially normal glucose, uh, and hemoglobin A1c, but we have trials ongoing now looking at, uh, pro-proactive management of hyperglycemia in patients with Type 2 diabetes and with pre-diabetes.

So they're testing inavolisib in, uh, INAVO-one-twenty-two, I think, uh, that is evaluating patients like a maintenance approach.

Uh, and the arm that recently closed to accrual, that should be presented in the near future, uh, is a, a dose expansion looking at elacestrant and capivasertib.

So that will be really helpful because, to my knowledge, there's-- that's gonna be one of the largest groups that's, that we have data on where you have an oral SERD and a drug that targets the PI3 kinase pathway.

All right, let's talk a little bit about Inavolisib.

We were talking about the Inavo-one-twenty study.